Biogen
BIIB
1,093 hedge funds and large institutions have $35.7B invested in Biogen in 2021 Q1 according to their latest regulatory filings, with 140 funds opening new positions, 357 increasing their positions, 409 reducing their positions, and 99 closing their positions.
86% more funds holding in top 10
Funds holding in top 10: 7 → 13 (+6)
41% more first-time investments, than exits
New positions opened: 140 | Existing positions closed: 99
12% more capital invested
Capital invested by funds: $31.7B → $35.7B (+$3.92B)
3% more funds holding
Funds holding: 1,060 → 1,093 (+33)
5% more call options, than puts
Call options by funds: $1.45B | Put options by funds: $1.37B
0.12% less ownership
Funds ownership: 84.06% → 83.93% (-0.12%)
13% less repeat investments, than reductions
Existing positions increased: 357 | Existing positions reduced: 409
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$263M |
| 2 |
Primecap Management
Pasadena,
California
|
+$252M |
| 3 |
SAM
Southeastern Asset Management
Memphis,
Tennessee
|
+$163M |
| 4 |
ClearBridge Investments
New York
|
+$99.9M |
| 5 |
A
AustralianSuper
Melbourne,
Australia
|
+$99.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$297M |
| 2 |
O
OrbiMed
New York
|
-$121M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$113M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$96.4M |
| 5 |
State Street
Boston,
Massachusetts
|
-$86.2M |
BIIB Hedge Fund Activity: Q1 2021 in Review
1,093 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2021, worth a combined $35.7B — up 12% from $31.7B a quarter earlier.
Buyers outnumbered sellers: 140 funds opened new BIIB positions and 99 closed out — a net gain of 41 holders — while 357 added to existing stakes and 409 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $263M. The largest seller was Renaissance Technologies, cutting an estimated $297M.
- 1,093 institutional investors held Biogen (BIIB) as of Q1 2021, up from 1,060 in Q4 2020.
- Funds reported $35.7B of Biogen stock for Q1 2021, up 12% quarter-over-quarter.
- 140 funds opened new Biogen positions in Q1 2021 and 99 closed out, a net change of +41 holders.
- The largest Biogen buyer in Q1 2021 was JP Morgan Chase, an estimated $263M added.
- The largest Biogen seller in Q1 2021 was Renaissance Technologies, an estimated $297M sold.
Based on aggregated 13F filings for Q1 2021.